Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02766465 · ClinicalTrials.gov registry record · Phase 2

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

A Phase 2 study, sponsored by Medical College of Wisconsin.

Completed
Registry status
Phase 2
Development phase
138
Enrollment target

NCT02766465: Completed Phase 2 study, sponsored by Medical College of Wisconsin.

NCT02766465 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 138 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02766465, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
Phase 2
Development phase
138 participants
Enrollment target

Study Summary

This is a clinical trial that will compare survival and sickle related outcomes in adolescents and young adults with severe sickle cell disease after bone marrow transplantation and standard of care. The primary outcome is 2-year overall survival.

Primary Outcome

Due to incomplete accrual, there was not adequate statistical power to analyze the primary endpoint as specified. Instead, point estimates for the observed proportion of patients surviving at two years post-biologic assignment in each arm were generated descriptively, with 95% CI, using the Kaplan Meier methodology. The event of interest was death from any cause.

Interventions

  • DRUG Fludarabine
  • DRUG Busulfan
  • DRUG Tacrolimus
  • PROCEDURE Hematopoietic Cell Transplant
  • DRUG r-ATG

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2017-03-16
Est. Completion 2023-08-02
Phase Phase 2
Medical College of Wisconsin

447 total trials

What the finished NCT02766465 record still lists

NCT02766465 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.

NCT02766465 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02766465 about?

NCT02766465 is a clinical study titled "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)". This is a clinical trial that will compare survival and sickle related outcomes in adolescents and young adults with severe sickle cell disease after bone marrow transplantation and standard of care. The primary outcome is 2-year overall survival.

What is the current status of trial NCT02766465?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2017-03-16. Estimated completion is 2023-08-02.

What interventions are being tested in trial NCT02766465?

The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Tacrolimus (DRUG), Hematopoietic Cell Transplant (PROCEDURE), r-ATG (DRUG).

Who is sponsoring clinical trial NCT02766465?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02766465's enrollment target sits among peer trials

138 525th of 2000 higher than 1,474 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02766465, the US trial registry maintained by the National Library of Medicine. NCT02766465 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.